Traitement hormonal de la ménopause et risque de thrombose veineuse - L’étude ESTHER ouvre de nouvelles perspectives

Marianne Canonico; Pierre-Yves Scarabin

doi:10.1051/medsci/2008243228

Accueil

Tous les numéros

Volume 24 / Numéro 3 (Mars 2008)

Med Sci (Paris), 24 3 (2008) 228-231

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 24, Numéro 3, Mars 2008


Page(s)		228 - 231
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/2008243228
Publié en ligne		15 mars 2008

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s health Initiative randomized controlled trial. JAMA 2002; 288 : 321–33. [Google Scholar]
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s health initiative randomized controlled trial. JAMA 2004; 291 : 1701–12. [Google Scholar]
Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17 : 3071–8. [Google Scholar]
Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362 : 428–32. [Google Scholar]
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115 : 840–5. [Google Scholar]
Aiach M, Alhenc-Gelas M, Borgel D, et al. Mutations des protéines de la coagulation et thromboses. Med Sci (Paris) 2006; 22 : 985–9. [Google Scholar]
Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112 : 3495–500. [Google Scholar]
Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER study. J Thromb Haemost 2006; 4 : 1259–65. [Google Scholar]
Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23 : 1671–6. [Google Scholar]
Arnal JF, Gourdy P, Garmy-Susini B, et al. Effets vasculaires des œstrogènes. Med Sci (Paris) 2003; 19 : 1226–32. [Google Scholar]
Rexrode KM, Manson JE. Are some types of hormone therapy safer than others ? Lessons from the Estrogen and Thromboembolism Risk study. Circulation 2007; 115 : 820–2. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s health Initiative randomized controlled trial. JAMA 2002; 288 : 321–33. [Google Scholar]

[2] Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s health initiative randomized controlled trial. JAMA 2004; 291 : 1701–12. [Google Scholar]

[3] Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17 : 3071–8. [Google Scholar]

[4] Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362 : 428–32. [Google Scholar]

[5] Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115 : 840–5. [Google Scholar]

[6] Aiach M, Alhenc-Gelas M, Borgel D, et al. Mutations des protéines de la coagulation et thromboses. Med Sci (Paris) 2006; 22 : 985–9. [Google Scholar]

[7] Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112 : 3495–500. [Google Scholar]

[8] Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER study. J Thromb Haemost 2006; 4 : 1259–65. [Google Scholar]

[9] Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23 : 1671–6. [Google Scholar]

[10] Arnal JF, Gourdy P, Garmy-Susini B, et al. Effets vasculaires des œstrogènes. Med Sci (Paris) 2003; 19 : 1226–32. [Google Scholar]

[11] Rexrode KM, Manson JE. Are some types of hormone therapy safer than others ? Lessons from the Estrogen and Thromboembolism Risk study. Circulation 2007; 115 : 820–2. [Google Scholar]